Toyobo
3101.TChemicals
Filed as TOYOBO CO., LTD. (2022-06–2026-06)
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥421.6bn | ¥422.0bn | ¥414.3bn | ¥399.9bn | ¥375.7bn | ¥337.4bn |
| Operating income | ¥27.9bn | ¥16.7bn | ¥9.0bn | ¥10.1bn | ¥28.4bn | ¥26.7bn |
| Ordinary income | ¥22.9bn | ¥10.6bn | ¥7.0bn | ¥6.6bn | ¥23.1bn | ¥20.7bn |
| Net income (owners) | ¥11.2bn | ¥2.0bn | ¥2.5bn | −¥655m | ¥12.9bn | ¥4.2bn |
| Total assets | ¥627.7bn | ¥617.8bn | ¥607.0bn | ¥588.9bn | ¥517.8bn | ¥491.2bn |
| Net assets / equity | ¥252.0bn | ¥232.0bn | ¥230.1bn | ¥221.4bn | ¥197.1bn | ¥188.6bn |
| Operating cash flow | ¥45.0bn | ¥30.1bn | ¥21.6bn | ¥7.8bn | ¥17.1bn | ¥35.0bn |
| EPS (basic) | ¥126.65 | ¥22.73 | ¥27.87 | ¥-7.37 | ¥144.75 | ¥47.3 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 6
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 203 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 203 figures · EDINET |
| 2023-04-01 → 2024-03-31 | AnnualAmended | 203 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 203 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 203 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 203 figures · EDINET |
21 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Life Science | ¥34.5bn | ¥65m |
| Real Estate | ¥4.5bn | ¥2.0bn |
| Other segments | ¥7.7bn | ¥1.1bn |
| Adjustments & eliminations | — | −¥2.9bn |
| Total | ¥413.9bn | ¥29.7bn |
| Total | ¥421.6bn | ¥30.8bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.